Sandoz

Sandoz Group AG
Formerly	Sandoz GmbH
Company type	Public (Aktiengesellschaft)
Traded as	SIX: SDZ; SMI MID component;
ISIN	CH1243598427
Industry	Biosimilars; Generics; Biopharmaceuticals;
Predecessor	Ciba-Geigy
Founded	1886
Founder	Alfred Kern; Edouard Sandoz;
Successor	Novartis
Headquarters	Basel, Switzerland
Key people	Richard Saynor (CEO); Francisco Ballester (President International);
Revenue	US$9.249 billion (2022)
Operating income	US$1.448 billion (2022)
Number of employees	28,000 (2022)
Website	sandoz.com
	Footnotes / references;

Sandoz Group AG is a Swiss-Germany based company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form the company Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland. Sandoz is one of the leading global generics business.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.